The Precision Medicine Catapult, the UK’s innovation centre for precision medicine, has entered into a strategic partnership with the UK Pharmacogenetics and Stratified Medicine Network.
The two organisations will work together to engage, promote and connect the precision medicine community through their websites, centres, events and workshops, both in the UK and overseas, ensuring better patient outcomes.
The Network was founded in 2010 by Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics at the University of Liverpool, following a Department of Health Genetics White Paper. Providing an essential link between academics, clinicians and others, its aim is to accelerate delivery of precision medicine to patients. There are over 400 individual members drawn from academia, medicine, industry, regulatory authorities and patient groups across the UK and elsewhere, the majority of whom are engaged in research into patient and/or disease stratification.
The Precision Medicine Catapult, created in April 2015 by Innovate UK, brings access to unique programmes, collaborations, initiatives and expertise from its global connections. Previously funded by the Department of Health and the Knowledge Transfer Network, the UK Pharmacogenetics and Stratified Medicine Network will now be supported by the Precision Medicine Catapult in its next stage of growth, and together the partners will drive the growth of the UK industry.
John McKinley, CEO of the Precision Medicine Catapult, said: “The UK Pharmacogenetics and Stratified Medicine Network has connected many of the leading stakeholders in the precision medicine landscape, so it makes perfect sense for our two organisations to partner and deliver engagement.”
Professor Sir Munir Pirmohamed, NHS Chair of Pharmacogenetics at the University of Liverpool, and founder of the UK Pharmacogenetics and Stratified Medicine Network, added: “With the Precision Medicine Catapult’s commitment to making precision medicine a reality in the UK, this partnership significantly increases the impact of our network’s activities. We expect this collaboration to be highly effective as we work together to develop the precision medicine solutions which are revolutionising healthcare.”